SVANOVIR® EHV1/EHV4-Ab

Pioneer ELISA for discriminating antibodies to Equine Herpesvirus type 1 and 4

**SUMMARY** | SVANOVIR® EHV1/EHV4-Ab is a highly discriminative test for detecting antibodies to Equine Herpesvirus (EHV) type 1 and type 4. The assay has been validated by different Universities showing the assays ability to contribute to correct management of EHV positive horses during outbreaks, tournaments and race-meetings.

---

**Your challenge** is a herpesvirus that has two main variants

The two major types of equine herpesvirus have different clinical significance. EHV-1 infections can cause severe respiratory infection, abortions, neonatal foal death, and myeloencephalopathy. In contrast, EHV-4 primarily causes respiratory disease. Both types can cause a lifelong latent infection with recurrent reactivation leading to clinical disease.

**Your goal** is to discriminate between antibodies of EHV-1 and EHV-4

EHV-1 and EHV-4 infections are ubiquitous, however, EHV-4 infection is more prevalent than EHV-1. Being able to discriminate between antibodies of the two types is of major importance to detect EHV-1 exposure and protect remaining horses from transmission. At the same time presence of EHV-4 should not initiate costly sanitation procedures and quarantine of affected horses which is indicated to prevent spread of EHV-1. Antibodies to EHV are highly cross reactive and thus highly specific tests are needed for accurate discrimination between the two types.

**ASSAY OVERVIEW**

<table>
<thead>
<tr>
<th>SVANOVIR® EHV1/EHV4-Ab</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Species</strong></td>
</tr>
<tr>
<td><strong>Samples</strong></td>
</tr>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td><strong>Article number</strong></td>
</tr>
<tr>
<td><strong>Samples</strong></td>
</tr>
<tr>
<td><strong>Plates</strong></td>
</tr>
<tr>
<td><strong>Format</strong></td>
</tr>
</tbody>
</table>

*Samples: Max. number of samples for analysis, wells for kit controls excluded

---

**The only ELISA that can discriminate between EHV-1 and EHV-4 infection**

**High accuracy** - the tool for detecting infection of EHV-1 in EHV-4 positive horses

**Evidence for decision making** – detects maternal antibodies and gives guidance to best time for vaccination to EHV-1 in foals

**Allows risk-classification of mares** into EHV-1 exposed and susceptible groups

**Developed in collaboration with the Centre for Equine Virology, University of Melbourne**

---

svanova
SVANOVIR® EHV1/EHV4-Ab is highly discriminative between EHV-1 and EHV-4 and is an effective and reliable tool for managing outbreak situations and classifying horses as free of EHV-1

Approved by the University of Kentucky as an easy-to-use tool offering good results rapidly

Time efficient – discriminate between EHV-1 and EHV-4 infection in one assay

Easy protocol and results in <3.5 hrs

High quality – validated and manufactured under strict ISO 9001:2008 standardised procedures in Sweden

**PERFORMANCE CHARACTERISTICS**

**SVANOVIR® EHV1/EHV4-Ab**

SVANOVIR® EHV1/EHV4-Ab can discriminate between infection with EHV-1, EHV-2 and detect EHV-1 and EHV-4 coinfection.

**Horse populations**

<table>
<thead>
<tr>
<th></th>
<th>EHV1</th>
<th>EHV4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposed to EHV1</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Exposed to EHV4</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Exposed to EHV1 &amp; EHV4</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

The ELISA was evaluated in experimentally and naturally infected individuals (Hartley et al., 2005; Crabb et al., 1995). In the experimental study on foals, SVANOVIR® EHV1/EHV4-Ab could clearly discriminate between EHV-1 and EHV-4 infection and did not provide false positive results as observed by virus neutralisation and complement fixation test.

![Figure: Comparison of serologic results from virus neutralisation (VN), complement fixation (CN) and SVANOVIR® EHV1/EHV4-Ab ELISA of serum samples from specific pathogen free foals before (pre-infection) and after infection (post EHV-1 or/and -4) Open bars: values for EHV-1, closed bars: values for EHV-4 (Hartley et al., 2005)]](image)


Boehringer Ingelheim Svanova
Box 1545
SE-751 45 Uppsala, Sweden

www.svanova.com